“I would say that to the low end of our guidance range from a revenue perspective would assume that the COVID franchise continues a very modest uptake for the balance of this year, particularly in the U.S.”

In context

“ow use in Phase III with reduced GI AE. So we are confident in the dose that was selected. Operator: We'll go next to Kerry Holford with Berenberg. Kerry Holford: Just on the guidance for this year, you've clearly reiterated the total revenue range of $61 to $64, but when you first set that guidance, you spoke of total COVID-19 sales of around $9 billion for the year, seeing that you booked only around just over $4 billion year-to-date. Just interested in your comments on whether that $9 billion is still achievable for the full year? And if not, what other assets would you call out as likely to fill that gap and give you confidence to reiterate the total sales guidance? Albert Bourla: Thank you. Dave, please? David Denton: Yes. On the -- you're absolutely right, Kerry, as you pointed out, I would say that to the low end of our guidance range from a revenue perspective would assume that the COVID franchise continues a very modest uptake for the balance of this year, particularly in the U.S. However, as you know, the COVID franchise is subject to peaks and valleys. If there happens to be a wave of COVID in the next several months, you can see utilization spike up. So that's why the range is so large. I'll just point out that what we have done with an earnings per share guidance range is we've derisked the COVID franchise with the guidance that we provided, given that if the trends continue, we'll be closer to the low end of that range, and we will still be able to deliver on our earnings commitment. Albert Bourla: Thank you, very clear, Dave. Let's move to the next question please. Operator: We'll go next to Mohit Bansal with Wells Fargo. Mohit Bansal: Just wanted to understand the thought process around the pricing of the GLP-1 and this class of medicines, given that -- I me”